Polivy (polatuzumab vedotin)

pCPA File Number: 21471
Negotiation Status:
Active Negotiation
Indication(s):
In combo with bendamustine & rituximab is indicated for the treatment of adult patients with relapsed or refractory DLBCL, not otherwise specified, who are not eligible for autologous stem cell transplant & have received at least one prior therapy.
Sponsor/Manufacturer:
HOFFMANN-LA ROCHE LIMITED
CADTH Project Number:
PC0227-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded:
Not Applicable